This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Covance's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Now please turn to Slide 5. In the third quarter, Early Development contributed 44% of net revenue and a Late-Stage contributed 56%. Also, 53% of our revenue came from the U.S., 15% from Switzerland, 11% from the U.K., 9% from countries in the eurozone and the remaining 12% from the rest of the world.

Now turn to Slide 6, please. In Early Development, in the third quarter, net revenues were $240 million, a 16.3% increase year-on-year or 14.9% net of the impact of foreign exchange. The year-on-year increase was driven by the addition of our Alnwick, U.K. and Porcheville, France sites, as well as strong growth in our Clinical Pharmacology, Analytical Chemistry and North American Toxicology services. Sequentially, revenues increased $8.4 million on growth in Clinical Pharmacology, Discovery Support services and Research Products operations, partially offset by a slight decline in Toxicology.

Third quarter operating income on a GAAP basis was $33.2 million and on a pro forma basis was $35 million or 14.6% of revenue. OM increased 40 basis points sequentially on margin expansion in Discovery Support, Clinical Pharmacology and North American Toxicology services.

Turning to Late-Stage Development. Net revenues in the third quarter was $303 million, up $17 million sequentially, and up 12% from the third quarter of last year or 4%, excluding the impact of foreign exchange. Growth in both periods was driven by continued strong performance of our Clinical Development services. Late-Stage Development operating income on a GAAP basis was $56.3 million and on a pro forma basis was $58.4 million or 19.3% of revenue, and that compares to 20% last quarter and 20.4% in the prior year. The sequential decline in profitability was partly -- or primarily, actually, due to normal seasonal factors coupled with significant increases in staffing levels in Clinical Development, which offset a sequential increase in margins in Central Labs.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,596.35 -350.33 -1.95%
S&P 500 2,057.64 -43.85 -2.09%
NASDAQ 4,958.4680 -122.0370 -2.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs